Based on univariate analysis, advanced age, HCV genotype 1, high pre-treatment HCV RNA level, advanced liver fibrosis, IL28B rs12979860 CT/TT, and the bAt (CCA) haplotype were significantly associated with poor response to PEG-IFN-based therapy. This evidence concerns the gene IFNL3 and Hepatic fibrosis.